-

Shareholder Alert: Robbins LLP Announces that Portland General Electric Co. (POR) is Being Sued for Misleading Shareholders

SAN DIEGO & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Portland General Electric Co. (NYSE: POR) has filed a class action complaint against the Company's officers for alleged violations of the Securities Exchange Act of 1934 between February 13, 2020 and August 24, 2020. Portland General Electric Co. is an integrated electric utility company that produces, acquires, and distributes electricity to customers in Oregon.

If you suffered a loss due to Portland General Electric Co.'s misconduct, click here.

Portland General Electric Co. (POR) Accused of Deceiving Consumers and Investors

According to the complaint, during the class period, the company falsely touted the strength of Portland General's business, financial, and operational profiles. On August 24, 2020, Portland General announced that it was taking a $128 million loss by its proprietary trading unit, which bet the wrong way on the energy trading market.

Changes in the wholesale energy markets in the summer of 2020 exposed these "ill-conceived" trades, forcing Portland General to disclose its trading unit, which investors did not even know existed. In conjunction with the loss, Portland General placed two employees on administrative leave and created a special committee to review the Company's energy trading practices. However, the loss caused Portland General to lower its earning guidance from $2.2-$2.5 per share to $1.3-$1.6 per share despite reaffirming the earning guidance a couple weeks earlier. On this news, Portland General's share price fell $3.95, or nearly 10%, during after-hours trading on August 24, 2020, and has yet to recover.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Portland General Electric Co. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom